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Diabetes mellitus is known to have late complications including micro vascular and macro
vascular disease. This review focuses on another possible area of complication regarding
diabetes; bone. Diabetes may affect bone via bone structure, bone density, and biochemical
markers of bone turnover.The aim of the present review is to examine in vivo from humans
on biochemical markers of bone turnover in diabetics compared to non-diabetics. Further-
more, the effect of glycemic control on bone markers and the similarities and differences
of type 1- and type 2-diabetics regarding bone markers will be evaluated. A systematic
literature search was conducted using PubMed, Embase, Cinahl, and SveMed+ with the
search terms: “Diabetes mellitus,” “Diabetes mellitus type 1,” “Insulin dependent diabetes
mellitus,” “Diabetes mellitus type 2,” “Non-insulin dependent diabetes mellitus,” “Bone,”
“Bone and Bones,” “Bone diseases,” “Bone turnover,” “Hemoglobin A Glycosylated,” and
“HbA1C.” After removing duplicates from this search 1,188 records were screened by title
and abstract and 75 records were assessed by full text for inclusion in the review. In the end
43 records were chosen. Bone formation and resorption markers are investigated as well
as bone regulating systems.T1D is found to have lower osteocalcin and CTX, while osteo-
calcin and tartrate-resistant acid are found to be lower in T2D, and sclerostin is increased
and collagen turnover markers altered. Other bone turnover markers do not seem to be
altered inT1D orT2D. A major problem is the lack of histomorphometric studies in humans
linking changes in turnover markers to actual changes in bone turnover and further research
is needed to strengthen this link.
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INTRODUCTION
Diabetes mellitus is a common disease in most parts of the world
(WHO, 2012; Wikipedia, 2012). Well known late complications
of diabetes are micro vascular disease including nephropathy,
retinopathy, neuropathy, and macro vascular disease such as acute
coronary syndrome, claudicatio intermittens, and stroke (Amer-
ican Diabetes Association, 2012). However, the bone turnover
and thus the skeletal integrity may also be affected by diabetes,
and diabetic bone disease can represent a hitherto overlooked
complication of diabetes. A meta-analysis reported lower bone
mineral density (BMD) z-score in T1D, but higher z-score in
Abbreviations: 1,25OHD, 1,25 dihydroxy vitamin D; 25OHD, 25 hydroxy vitamin
D; AP, alkaline phosphatase; BAP, bone-specific alkaline phosphatase; BMD, bone
mass density; BMI, body mass index; CICP, collagen type 1 C propeptide; CTX, C-
terminal cross-linked telopeptide of type-I collagen; DPD, deoxypyridinoline; FPG,
fasting plasma glucose; HbA1C, glycated hemoglobin; HP, hydroxyproline; IDD,
insulin dependent diabetes; IGF-1, insulin like growth factor-1; NIDD, non-insulin
dependent diabetes; NTX, N-terminal cross-linked telopeptide of type-I collagen;
OC, osteocalcin; OPG, osteoprotegerin; P1CP, procollagen type 1 carboxyl terminal
propeptide; P1NP, procollagen type 1 amino terminal propeptide; PTH, parathy-
roid hormone; PYR, pyridinoline; RANK, receptor activator of nuclear factor kappa
beta; RANKL, receptor activator of nuclear factor kappa beta ligand; S-, serum; Scl,
sclerostin; T1D, type 1 diabetes; T2D, type 2 diabetes; TRAP, tartrate-resistant acid
phosphatase; U-, urine; ucOC, undercarboxylated osteocalcin.
T2D compared to controls (Vestergaard, 2007). Despite the higher
BMD, patients with T2D have more fractures than non-diabetic
controls (Vestergaard, 2007). Patients with T1D also have more
hip fractures than can be explained by the decreased BMD (Vester-
gaard, 2007). The increased fracture risk is supported by a larger
Danish study, where diabetics without late complications had a rel-
ative risk of any fracture of 1.21 (1.07–1.36) for T1D and of 1.13
(1.06–1.22) for T2D (Vestergaard et al., 2009). This may point
at a weakening of bone biomechanical competence beyond what
can be measured by BMD. This disruption of biomechanical com-
petence may be brought about by alterations in bone turnover
and non-calcium bone matrix (such as collagen), as BMD mainly
reflects calcium content in the bone.
BONE TURNOVER IN GENERAL
Bone turnover is a dual relationship between the process of
bone formation by osteoblasts (creation of new bone) and the
process of bone resorption by osteoclasts (removal of old bone)
(Delmas, 1991; Garnero, 2009). Bone markers are subdivided
into bone formation and bone resorption markers. Bone forma-
tion markers consist of osteocalcin (OC), bone-specific alkaline
phosphatase (BAP), alkaline phosphatase (AP), osteoprotegerin
(OPG), procollagen type 1 amino terminal propeptide (P1NP),
and procollagen type 1 carboxyl terminal propeptide (P1CP)
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(Delmas, 1991; Garnero, 2009), while resorptive markers consist
of N-terminal cross-linked telopeptide of type-I collagen (NTX),
C-terminal cross-linked telopeptide of type-I collagen (CTX),
tartrate-resistant acid phosphatase (TRAP), RANKL (Receptor
Activator of Nuclear factor Kappa beta Ligand), pyridinoline
(PYR), deoxypyridinoline (DPD), hydroxyproline (HP), and scle-
rostin (Scl) (Delmas, 1991; Manolagas and Almeida, 2007; Gar-
nero, 2009). Scl, OPG, and RANKL are not markers in strict sense,
but are included in this section, since they are related to bone
turnover (see below). These markers represent products secreted
by cells such as OC and Scl and enzymes (alkaline and acid phos-
phatase), collagen cleavage products as examples of the organic
matrix, and calcium itself. Figure 1 gives an overview of some of
the different systems (described below) regulating bone turnover.
BIOCHEMICAL MARKERS SECRETED BY BONE CELLS
(a) Osteocalcin is a valid marker of bone turnover both when for-
mation and resorption are uncoupled as well as when formation
and resorption are coupled (Delmas, 1991). However, OC fluctu-
ates with food intake making it susceptible to error and it may be
questioned if the serum marker fully reflects what is going on in
the bone in diabetics. OC becomes γ-carboxylated at three gluta-
mine terminals so it can interact with hydroxyapatite, when fewer
than three terminals are γ-carboxylated it is undercarboxylated
OC (ucOC) (Motyl et al., 2010). Besides being a marker of bone
formation, OC and UcOC are also associated with beta-cell func-
tion and insulin sensitivity and thus control of plasma glucose
levels (Lee et al., 2007; Ferron et al., 2008; Confavreux et al., 2009).
UcOC is suggested to stimulate the secretion of adiponectin from
adipocytes (Motyl et al., 2010; Ng, 2011). In mice, OC injections
prevent T2D and improve glucose control (Ferron et al., 2012).
Furthermore, a human study concluded that OC is associated
with improved glucose tolerance and insulin secretion (Hwang
et al., 2012). Glycemic control has been linked to increased OC
(Motyl et al., 2010; Bao et al., 2011), although the mechanisms
are unclear. (b) Both AP and BAP are bone formation markers
measured in serum. While BAP is specific for bone, AP consists
of different iso-enzymes like the hepatic AP (Delmas, 1991). (c)
TRAP is an enzyme in different subtypes including an osteoclast
specific enzyme (TRAP-5b) (Garnero, 2009). TRAP-5b is a marker
that reflects the number and activity of osteoclasts and shows little
variation regarding time of day and food intake (Garnero, 2009).
(d) Scl is a Wnt-pathway antagonist produced in the osteocytes
(Gennari et al., 2012). The Wnt-pathway promotes osteoblastoge-
nesis, increases OPG expression, and decreases osteoclastogenesis
and bone resorption (Manolagas and Almeida, 2007).
BIOCHEMICAL MARKERS OF COLLAGEN
P1NP and P1CP are secreted to the blood after their cleavage from
collagen (Delmas, 1991). Both P1NP and CTX fluctuate rapidly
with glucose intake (Clowes et al., 2003), and may thus be less
precise. The rapid fluctuations with glucose intake make it ques-
tionable if these markers truly reflect what is going on in the
bone during hyperglycemia. PYR is found in collagen of bone, but
also in other tissues, while DPD is only at significant amounts in
bone collagen (Delmas, 1991). PYR and DPD are mature collagen
crosslinks released by collagen breakdown and is thus measurable
markers (Calvo et al., 1996). Some of these crosslinks are released
in peptide-bound forms (CTX, NTX), which are shown useful
in bone assessment (Calvo et al., 1996; Achemlal et al., 2005).
FIGURE 1 | Overview of different systems regulating bone metabolism in
its relationship with each other and effects on osteoblasts and
osteoclasts as mentioned in the Section “Introduction” above. Figure 1
shows that the systems regulating bone metabolism are in a complex
relationship to each other. Green arrows indicate a stimulating action, while
blue arrows indicate a inhibiting action.
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Since DPD is a limited marker, it seems more specific and sensitive
regarding bone resorption than PYR (Miazgowski and Czekalski,
1998). HP is found in collagens of different tissues and after its
release, during collagen breakdown, most of it is reabsorbed in the
kidneys and oxidized in the liver. HP thus does not reflect the total
collagen catabolism (Delmas, 1991).
CALCIUM
Serum (s-) calcium is tightly regulated by the calcitropic hormones
(see below) and thus often is a poor marker of bone turnover. Uri-
nary (u-) calcium may be used as a marker of bone resorption, but
is rather variable with calcium intake and thus requires standard-
ized sampling. For these reasons it is rarely used as a marker of
bone turnover in clinical practice. In diabetics, hyperglycemia may
be associated with increased loss of calcium in the urine (Raskin
et al., 1978; McNair et al., 1979).
CALCITROPIC HORMONES
The calcium, PTH, and vitamin D system is tightly related to
bone metabolism. PTH is secreted from the parathyroid glands
and is a regulator of 1,25OHD production, calcium absorption,
and bone calcium release. PTH inhibits Scl production in humans
(Garcia-Martin et al., 2012a), thereby influencing bone formation
by multiple pathways. Vitamin D acts by stimulating the intestinal
absorption of calcium and is a regulator of the calcium home-
ostasis. Vitamin D stimulates the synthesis of OC (Inaba et al.,
1999). Calcitonin affects osteoclasts by inhibiting bone resorption
and affects the kidney by enhancing urinary calcium excretion
(Pondel, 2000).
THE OPG/RANKL SYSTEM
The OPG/RANKL system is a part of the bone turnover metab-
olism. RANKL is the agonist in regulating important aspects of
osteoclasts like differentiation, fusion, survival, activation, and
apoptosis (Horowitz et al., 2001). RANKL acts by activating a
specific receptor (RANK – Receptor Activator of Nuclear factor
Kappa beta) on the osteoclasts and promoting bone resorption,
making RANKL a marker of bone resorption (Horowitz et al.,
2001). In contrast, OPG is the antagonist to RANKL (Galluzzi et al.,
2005). Another inhibitor of RANKL seems to be hyperglycemia,
which induces low bone turnover and suppresses osteoclastogene-
sis (Wittrant et al., 2008). Again the question is whether the serum
markers truly reflect what is going on in the bone as no biopsy
studies are available.
BONE–FAT INTERACTION
Fat tissue is suggested to be an actor in both diabetes and bone
metabolism. T2D patients are often overweight and present with
issues related to this (American Diabetes Association, 2012).
(a) Adiponectin is secreted by fat tissue, and a receptor for
adiponectin on osteoblasts has been identified (Berner et al., 2004;
Kanazawa et al., 2007). Adiponectin is suggested to stimulate
proliferation, differentiation, and mineralization of osteoblasts
(Berner et al., 2004; Luo et al., 2005; Kanazawa et al., 2007). It
is proposed that adiponectin plays a role in energy metabolism
by increasing insulin sensitivity, reducing endogenous glucose
production, and decreasing serum glucose levels (Berg et al.,
2001; Combs et al., 2001). Adiponectin affects the RANKL/OPG
system by stimulating RANKL and inhibiting OPG production
in osteoblasts, thereby promoting osteoclast formation and bone
resorption (Luo et al., 2006). (b) Another fat tissue marker, lep-
tin, is found to suppress osteoclast and bone resorption in vitro
by inhibiting RANKL and may increase bone mass (Holloway
et al., 2002; Reid, 2002). Leptin also increases proliferation and
differentiation of osteoblasts (Reid, 2002).
THE IGF SYSTEM AND ADVANCED GLYCATION END PRODUCTS
Another aspect of bone turnover is the effect of insulin and insulin
like products. Insulin like growth factor-1 (IGF-1) is an important
anabolic regulator of the bone, which mainly is produced in the
liver but other tissues as well like in the osteoblasts (Verhaeghe
et al., 1992; Johansson et al., 1996; Yakar et al., 2002). In T2D, IGF
levels may be increased (Frystyk et al., 1999). In addition insulin
is believed to promote osteoblastogenesis and increase bone for-
mation (Reid et al., 1993; Reid, 2002). In contrast, oxidative stress
and the production of advanced glycation end products (AGE)
are associated with inhibition of osteoblast differentiation and
to osteoblast apoptosis, thus leading to reduced osteoblast func-
tion (Alikhani et al., 2007; Hamada et al., 2009). Oxidative stress
also antagonizes the before mentioned Wnt-pathway and therefore
inhibits osteoblast activity (Manolagas and Almeida, 2007).
AIM
The aim of the present review is to:
(a) Examine in vivo human evidence on the connection between
diabetes mellitus and bone markers compared to non-
diabetics and collate the different markers with each other.
(b) Evaluate the effect of glycemic control in diabetics on bone
markers and assess the similarities and differences between
type 1- and type 2-diabetics.
METHODS
To perform this review a literature search was conducted in
association with a research librarian. The databases, PubMed,
Embase, Cinahl, SveMed+, Cochrane library, and Bibliotek.dk
were screened using the search terms: “Diabetes mellitus,” “Dia-
betes mellitus type 1,” “Insulin dependent diabetes (IDD) melli-
tus,” “Diabetes mellitus type 2,” “Non-insulin dependent diabetes
(NIDD) mellitus,” “Bone,” “Bone and Bones,” “Bone diseases,”
“Bone turnover,”“Hemoglobin A Glycosylated,” and “HbA1C.” In
total 1,188 records were retrieved from the literature search. Dupli-
cates were removed and records screened by title and abstract. The
records were screened so they are of a cross-sectional, retrospec-
tive, case-control, or prospective design. The eligibility criteria to
the studies are; that they shall examine bone turnover markers in
relationship to diabetics with or without a control group. Stud-
ies assessing the effect of different medications were excluded.
By these criteria 1,113 records were removed. The remaining
75 records were assessed in full text for inclusion in the review
by the same eligibility criteria as above. In the end 43 records
were included in this review. Of the 43 records; 32 were of a
cross-sectional design, and 11 were of a prospective design.
Some of the records did not subdivide diabetics in T1D and in
T2D, but rather subdivided as IDD and NIDD. The IDD and NIDD
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subdivision is mainly used in studies of older date (all before year
2000). In the following, IDD will be treated as T1D and NIDD will
be treated as T2D. However insulin treated T2D may be included
in IDD, while NIDD cannot be T1D (which is an IDD type). This
may be a setback, still only four studies used IDD as diabetes sub-
division (see Tables 1–4), which makes the usage of T1D and IDD
as one, a minor issue to the review. Furthermore when glycemic
control and 7 years of insulin therapy are mentioned it means a sig-
nificant decrease in HbA1c or a decrease in FPG. The study using
FPG do not conclude whether the drop is significant (Gregorio
et al., 1994).
DATA ON MARKERS
Table 1 shows details on the calcitropic system in diabetics, Table 2
shows details on bone formation markers in diabetics, Table 3
shows details on bone resorption markers in diabetics, and Table 4
shows details on other bone markers in diabetics. An overview of
the markers that seem to differ in diabetics is shown in Figure 2.
CALCIUM
For data on s-calcium and u-calcium, see Table 1. In summary,
s-calcium and u-calcium seem not to differ between either T1D or
T2D and controls. S-calcium is higher in T2D women than men,
with evidence from one study that this may be caused by their
postmenopausal state (Rasul et al., 2012a), while another was not
informative on this (Pedrazzoni et al., 1989). S-calcium may show
a small but significant increase in T2D (2.1 vs. 2.4 mmol/l) (Hamil-
ton et al., 2012) over time and poor glycemic control may result in
a fall in u-calcium.
PARATHYROID HORMONE
For data on s-PTH, see Table 1. It is unlikely that renal dysfunc-
tion has affected the results, since one study adjusted by creatinine
clearance (Dobnig et al., 2006), while all others, expect one (Gerd-
hem et al., 2005), excluded participants with renal impairment. In
summary, s-PTH is likely to be variable in T1D and T2D, since it
has been reported to be unchanged, higher, and lower. In T2D the
absence of a difference is most likely as it was found by the majority
of studies. S-PTH seems not to correlate to BMD in T1D or T2D
nor is it likely to differ over time in T1D and T2D, although Vita-
min D stimulation decreases s-PTH. Glycemic control is, in T1D,
likely to result in a rather large increase in s-PTH, while glycemic
control in T2D most likely does not change s-PTH.
SERUM 1,25 VITAMIN D AND 25 VITAMIN D
For data regarding 1,25 vitamin D and 25 vitamin D, see Table 1.
To summarize S-25OHD is likely to be lower in T1D than con-
trols, while both s-25OHD and s-1,25OHD are most likely not
to differ between T2D and controls, since the majority of studies
reported no difference. S-25OHD may decrease over time in T2D,
but not in T1D. The lower s-25OHD levels in T2D may be due
to an increased mean age of these individuals (Hamilton et al.,
2012). Furthermore glycemic control seems not change s-25OHD
in T2D.
CALCITONIN
For data on calcitonin, see Table 1. In summary, calcitonin seems
higher in T1D (P > 0.05) than controls, although it is in normal
value range, and not to differ in T2D in comparison to controls.
However, the number of studies is limited.
ALKALINE PHOSPHATASE
For data on s-AP, see Table 2. To sum up s-AP seems not to dif-
fer in T1D and T2D in comparison to controls, since the largest
studies showed no difference (Oz et al., 2006; Zhou et al., 2010;
Hamed et al., 2011; Shu et al., 2012). Over time s-AP may increase
in T1D, which can be caused by hepatic involvement (Hamilton
et al., 2012), since other bone markers (s-OC, s-CTX, u-PYR, u-
DPD) do not differ. S-AP is also reported not to differ in T1D and
T2D over time, nor to change by glycemic control in T1D.
BONE-SPECIFIC ALKALINE PHOSPHATASE
For data on s-BAP, see Table 2. In summary, s-BAP is most likely
not to differ in either T1D or T2D in comparison to controls.
S-BAP seems lower in T2D males than T2D females, which may
reflect the postmenopausal state in the females (Kanazawa et al.,
2011b). S-BAP may not correlate to HbA1c or change over time
in T2D, nor is it likely to change by glycemic control in both T1D
and T2D.
OSTEOCALCIN
For data on s-OC, see Table 2. In summary, s-OC is likely to
be up to four times lower in young T1D than controls (12.2 vs.
49.4 ng/ml) (Abd El Dayem et al., 2011) and somewhat lower
in older T1D than controls. A negative relationship to pubertal
development is probable in T1D, whereas s-OC may normalize
in adulthood. S-OC is likely not to correlate to BMD in T1D,
but to have a positive relationship to s-CTX and a negative rela-
tionship to HbA1c. In T2D s-OC is most likely to be somewhat
lower than among controls, as the studies reporting a lower s-
OC includes larger populations. Also s-OC is probably negatively
associated with HbA1c in T2D. Regarding the longitudinal stud-
ies; s-OC is most likely not to change in T1D and T2D over time,
while glycemic control neither seem to change s-OC in T1D. How-
ever, in T2D, glycemic control may either not change, decrease, or
increase s-OC, where the studies finding a decrease were the ones
including the longest period of time and therefore supporting a
decrease. Overall, changes in s-OC are likely to relate to changes
in HbA1c.
UNDERCARBOXYLATED OSTEOCALCIN
For data on s-ucOC, see Table 2. To sum up, s-ucOC seems twice
as low in diabetics on hemodialysis (14.4 vs. 31.5 ng/ml) (Okuno
et al., 2013) than matched controls and almost half the level in
T2D males compared females, which may be explained by the
postmenopausal state in the females. S-ucOC appears positively
related to bone turnover markers and negatively to HbA1c, while
glycemic control does not to change ucOC.
PROCOLLAGEN TYPE 1 AMINO TERMINAL PROPEPTIDE, PROCOLLAGEN
TYPE 1 C PROPEPTIDE, AND COLLAGEN TYPE 1 C PROPEPTIDE
For data on s-P1NP, s-PICP, and s-CICP, see Table 2. To summa-
rize, s-P1NP is likely to be somewhat lower in T2D than controls
(see Table 2). On the other hand, neither s-PICP nor s-CICP,
are likely to differ regarding T2D, while s-CICP may be somewhat
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Table 1 | Calcitropic system markers.
Marker Study type Reference Diabetes type *
s-Calcium Cross-sectional Dobnig et al. (2006) T2D ↑
Levy et al. (1986) T2D ↑
Rasul et al. (2012a) T2D women vs. men ↑
Pedrazzoni et al. (1989) IDD men ↑
NIDD women ↑
NIDD men ↑
Achemlal et al. (2005) T2D men →
Gregorio et al. (1994) NIDD PMC →
NIDD GMC →
Hampson et al. (1998) T1D PM →
T2D PM →
Shu et al. (2012) T2D PM →
Cutrim et al. (2007) T2D GMC →
T2D PMC →
Zhou et al. (2010) T2D PM (BMI ≥25) →
T2D PM (BMI <25) →
Garcia-Martin et al. (2012b) T2D →
Oz et al. (2006) T2D →
Rasul et al. (2012b) T2D men PNP →
T2D women PNP →
Neumann et al. (2011) T1D women →
T1D men →
Abd El Dayem et al. (2011) T1D →
Hamed et al. (2011) T1D ↓
Longitudinal Hamilton et al. (2012) T2D ↑
T1D →
Glycemic control Campos Pastor et al. (2000) T1D ↑
Capoglu et al. (2008) T2D →
u-Calcium Cross-sectional Achemlal et al. (2005) T2D men →
Gregorio et al. (1994) NIDD PMC →
NIDD GMC →
Oz et al. (2006) T2D →
Longitudinal Inaba et al. (1999) (mg/mg) T2D DS ↑
PTH Cross-sectional Hamed et al. (2011) T1D ↑
Gennari et al. (2012) T1D ↑
Gregorio et al. (1994) NIDD PMC ↑
Galluzzi et al. (2005) T1D →
Neumann et al. (2011) T1D women →
Hampson et al. (1998) T1D PM →
Gennari et al. (2012) T2D →
Hampson et al. (1998) T2D PM →
Achemlal et al. (2005) T2D men →
Oz et al. (2006) T2D →
Shu et al. (2012) T2D PM →
Cutrim et al. (2007) T2D GMC →
T2D PMC →
Zhou et al. (2010) T2D PM (BMI ≥25) →
→
Gregorio et al. (1994) NIDD GMC →
Rasul et al. (2012a) T2D men vs. women →
(Continued)
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Table 1 | Continued
Marker Study type Reference Diabetes type *
Rasul et al. (2012b) T2D men PNP →
T2D women PNP →
Gerdhem et al. (2005) Diabetic women →
Neumann et al. (2011) T1D men ↓
Pedrazzoni et al. (1989) IDD women ↓
IDD men ↓
NIDD women ↓
NIDD men ↓
Garcia-Martin et al. (2012b) T2D ↓
Dobnig et al. (2006) T2D NH ↓
Reyes-Garcia et al. (2013) T2D ↓
Okuno et al. (2013) Diabetics HD ↓
Longitudinal Hamilton et al. (2012) T1D men →
T1D women →
T2D men →
T2D women →
Inaba et al. (1999) T2D DS ↓
Glycemic control Campos Pastor et al. (2000) T1D ↑
Capoglu et al. (2008) T2D →
Rosato et al. (1998) NIDD men →
NIDD women →
Gregorio et al. (1994) NIDD PMC ↓
25OHD Cross-sectional Galluzzi et al. (2005) T1D →
Garcia-Martin et al. (2012b) T2D →
Gregorio et al. (1994) NIDD GMC →
NIDD PMC →
Hampson et al. (1998) T2D PM →
Shu et al. (2012) T2D PM →
Cutrim et al. (2007) T2D GMC →
T2D PMC →
Dobnig et al. (2006) T2D NH →
Reyes-Garcia et al. (2013) T2D →
Rasul et al. (2012a) T2D men vs. women →
Rasul et al. (2012b) (nM/l) T2D men PNP →
T2D women PNP →
Gerdhem et al. (2005) Diabetic women →
Gennari et al. (2012) T1D ↓
Hampson et al. (1998) T1D PM ↓
Hamed et al. (2011) T1D ↓
Gennari et al. (2012) T2D ↓
Longitudinal Hamilton et al. (2012) T1D →
T2D ↓
Glycemic control Capoglu et al. (2008) T2D →
Rosato et al. (1998) NIDD men →
NIDD women →
1,25OHD Cross-sectional Gregorio et al. (1994) NIDD GMC →
NIDD PMC →
Shu et al. (2012) T2D PM →
(Continued)
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Table 1 | Continued
Marker Study type Reference Diabetes type *
Rasul et al. (2012b) T2D men PNP →
T2D women PNP →
Rasul et al. (2012a) T2D men vs. women →
Calcitonin Cross-sectional Pedrazzoni et al. (1989) IDD women ↑
IDD men ↑
NIDD women ↑
NIDD men ↑
Gregorio et al. (1994) NIDD GMC →
NIDD PMC →
Zhou et al. (2010) T2D PM (BMI ≥25) →
T2D PM (BMI <25) →
Glycemic control (during the longitudinal study); ∗, statistically significantly different; ↑, significantly higher in diabetics; ↓, significantly lower in diabetics;→, without
significance; GMC, good metabolic control; PMC, poor metabolic control; PM, postmenopausal; NH, nursing home; age ≥70; HD, hemodialysis; PNP, polyneuropathy.
lower in T1D supported by a larger study population (see Table 2).
S-CICP is also probable to be negatively correlated to BMD in T1D.
TARTRATE-RESISTANT ACID PHOSPHATASE
For data on s-TRAP, see Table 3. S-TRAP-5b is likely to be much
lower in T2D than controls. Also s-TRAP seems not to correlate to
HbA1c; however it seems to undergo a somewhat large decrease
during glycemic control in T1D.
CARBOXY-TERMINAL TELOPEPTIDE OF TYPE 1 COLLAGEN
For data on s-CTX, see Table 3. In summary, s-CTX is very likely
to be up to twice as low in T2D and T1D, when both are compared
to controls, since both are reported with convincing significance
(P < 0.001). Over time s-CTX seems to increase twofold in com-
parison to the baseline value (0.26 vs. 0.13 ng/ml) in T2D females,
but not in T2D males or T1D, which could be caused by the prob-
able postmenopausal state due to higher mean age in these T2D
females (70 at follow up), while T1D females had a lower mean
age (53 at follow up) (Hamilton et al., 2012).
N-TELOPEPTIDE
For data on N-telopeptide, see Table 3. To summarize, s-NTX is
unlikely to differ in either T2D or T1D, but seems to have a neg-
ative association with HbA1c in T1D. However, few studies are
available.
URINARY N-TERMINAL CROSS-LINKED TELOPEPTIDE OF TYPE-I
COLLAGEN
For data on u-NTX, see Table 3. To sum up, u-NTX is likely to be
higher in T2D than controls and be almost twice as low in T2D
men as women (see Table 3), which may relate to the fact that these
women are postmenopausal (Kanazawa et al., 2011b). U-NTX is
in T2D likely to correlate negatively to BMD, but not to correlate
to HbA1c. Over time, u-NTX does not seem to change in T1D.
During glycemic control through 12 months T2D may decrease in
u-NTX (Capoglu et al., 2008), while shorter periods do not seem
to affect u-NTX.
DEOXYPYRIDINOLINE, PYRIDINOLINE
For data on u-DPD and u-PYR, see Table 3. In summary, u-DPD
may be twice the value in young T1D as controls (Abd El Dayem
et al., 2011), while it seems to normalize in adulthood. In T2D,
u-DPD is likely not to differ, although unspecified diabetics seem
to have lower u-DPD than controls. U-DPD seems not to correlate
to BMD in T1D. Nor is u-DPD likely to change over time in T1D
and T2D as well as u-PYR does not change in T1D. Furthermore,
during glycemic control u-PYR seems to increase in T2D, while
u-DPD, on the other hand, is likely to decrease.
HYDROXYPROLINE AND CROSSLAPS
For data on u-HP and u-crosslaps, see Table 3. In summary, u-
crosslaps is likely to be lower in T2D than controls. U-HP seems
to be positively associated with HbA1c (Gregorio et al., 1994).
OSTEOPROTEGERIN AND RANKL
For data on OPG and RANKL, see Table 4. In summary s-RANKL
is likely not to differ in T1D, while s-OPG may be lower in T1D,
since this is supported by a larger study.
SCLEROSTIN
For data on s-Scl, see Table 4. Also, s-Scl tended to correlate pos-
itively to HbA1c levels in T2D patients, however the correlation
was not statistically significant (Garcia-Martin et al., 2012b; Gen-
nari et al., 2012). In relation to BMD, s-Scl is in T2D reported to
positively relate toT -score in lumbar spine, femoral neck, and total
hip (P < 0.05) (Garcia-Martin et al., 2012b) and s-Scl levels are
lower in osteoporotic- than non-osteoporotic-T2D (P = 0.048)
(Garcia-Martin et al., 2012b). In summary, s-Scl is likely to be
higher in T2D than both T1D and controls. S-Scl tends to be posi-
tively related to HbA1c and is likely to be positively related to BMD
in T2D.
ADIPONECTIN AND LEPTIN
For data on adiponectin, see Table 4. In summary, s-adiponectin is
likely to be higher in T2D women than T2D men,which may be due
to postmenopausal state among the women studied (Kanazawa
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Table 2 | Bone formation markers.
Marker Study type Reference Diabetes type *
AP Cross-sectional Cutrim et al. (2007) T2D PMC ↑
Pedrazzoni et al. (1989) NIDD men ↑
Pedrazzoni et al. (1989) IDD men ↑
Cutrim et al. (2007) T2D GMC →
Oz et al. (2006) T2D →
Shu et al. (2012) T2D PM →
Zhou et al. (2010) T2D PM (BMI ≥25) →
Zhou et al. (2010) T2D PM (BMI <25) →
Hamed et al. (2011) T1D →
Pedrazzoni et al. (1989) IDD women →
Pedrazzoni et al. (1989) NIDD women ↓
Longitudinal Miazgowski and Czekalski (1998) IDD ↑
Hamilton et al. (2012) T1D men ↑
T1D women ↑
T2D men →
T2D women →
Glycemic control Campos Pastor et al. (2000) T1D →
BAP Cross-sectional Kanazawa et al. (2011b) T2D PM vs. men ↑
Rasul et al. (2012b) T2D women PNP ↑
Gennari et al. (2012) T1D →
Garcia-Martin et al. (2012b) T2D →
Shu et al. (2012) T2D PM →
Reyes-Garcia et al. (2013) T2D →
Gerdhem et al. (2005) Diabetic women →
Okuno et al. (2013) Diabetic HD →
Rasul et al. (2012a) T2D men vs. women →
Gennari et al. (2012) T2D ↓
Oz et al. (2006) T2D ↓
Rasul et al. (2012b) T2D men PNP ↓
Longitudinal Miazgowski et al. (2012) T2D PM →
Inaba et al. (1999) T2D →
Glycemic control Kanazawa et al. (2011a) T2D ↑
Campos Pastor et al. (2000) T1D →
Capoglu et al. (2008) T2D ↓
Kanazawa et al. (2009b) T2D ↓
OC Cross-sectional Aboelasrar et al. (2010) T1D PrP vs. Pb ↑
Rasul et al. (2012b) T2D men PNP ↑
Gregorio et al. (1994) NIDD PMC ↑
Gennari et al. (2012) T1D →
Pedrazzoni et al. (1989) IDD women →
Leon et al. (1989) T1D →
Gennari et al. (2012) T2D →
Garcia-Martin et al. (2012b) T2D →
Gregorio et al. (1994) NIDD PMC →
Cutrim et al. (2007) T2D GMC →
Reyes-Garcia et al. (2013) T2D →
Rasul et al. (2012a) T2D men vs. women →
Rasul et al. (2012b) T2D women PNP →
Neumann et al. (2011) T1D men ↓
T1D women ↓
(Continued)
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Table 2 | Continued
Marker Study type Reference Diabetes type *
Abd El Dayem et al. (2011) T1D ↓
Aboelasrar et al. (2010) T1D ↓
Lappin et al. (2009) T1D LH ↓
T1D HH ↓
Danielson et al. (2009) T1D ↓
Brandao et al. (2007) T1D girls vs. boys ↓
Pedrazzoni et al. (1989) IDD men ↓
Christensen and Svendsen (1999) IDD PrM vs. PM ↓
NIDD PrM vs. PM ↓
Pedrazzoni et al. (1989) NIDD women ↓
NIDD men ↓
Achemlal et al. (2005) T2D men ↓
Oz et al. (2006) T2D ↓
Dobnig et al. (2006) T2D NH ↓
Shu et al. (2012) T2D PM ↓
Cutrim et al. (2007) T2D PMC ↓
Zhou et al. (2010) T2D PM (BMI ≥25) ↓
T2D PM (BMI <25) ↓
Gregorio et al. (1994) NIDD GMC ↓
Kanazawa et al. (2011b) T2D men vs. PM ↓
Gerdhem et al. (2005) Diabetic women ↓
Longitudinal Miazgowski and Czekalski (1998) IDD ↑
Hamilton et al. (2012) T1D men →
T1D women →
T2D men →
T2D women →
Mastrandrea et al. (2008) T1D <20 →
Mastrandrea et al. (2008) T1D ≥20 ↓
Glycemic control Kanazawa et al. (2009b) T2D ↑
Rosato et al. (1998) NIDD men ↑
NIDD women ↑
Kanazawa et al. (2011a) T2D →
Campos Pastor et al. (2000) T1D →
Capoglu et al. (2008) T2D ↓
Gregorio et al. (1994) NIDD PMC ↓
ucOC Cross-sectional Rosato et al. (1998) NIDD men ↑
NIDD women ↑
Okuno et al. (2013) Diabetic HD ↓
Glycemic control Kanazawa et al. (2009b) T2D →
P1NP Cross-sectional Rasul et al. (2012b) T2D men PNP ↑
Rasul et al. (2012a) T2D men vs. women →
Rasul et al. (2012b) T2D women PNP →
Shu et al. (2012) T2D PM ↓
PICP Cross-sectional Cutrim et al. (2007) T2D GMC →
T2D PMC →
CICP Cross-sectional Hampson et al. (1998) T1D PM →
T2D PM →
(Continued)
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Table 2 | Continued
Marker Study type Reference Diabetes type *
Oz et al. (2006) T2D →
Lappin et al. (2009) T1D LH →
T1D HH →
Abd El Dayem et al. (2011) T1D ↓
Glycemic control (during the longitudinal study); ∗, statistically significantly different; ↑, significantly higher in diabetics; ↓, significantly lower in diabetics;→, without
significance; GMC, good metabolic control; PMC, poor metabolic control; PM, postmenopausal; NH, nursing home; age ≥70; HD, hemodialysis; PNP, polyneuropathy;
PrM, premenopausal; LH, low HbA1c <8.5; HH, high HbA1c >8.5; ≥20, 20 years old or more; <20, younger than 20 years; Pb, pubertal; PrP, prepubertal.
et al., 2009a). It is uncertain whether s-adiponectin is related to
bone turnover markers, while s-leptin seems to have a negative
relationship to u-NTX. Moreover glycemic control seems not to
change s-adiponectin in T2D.
IGF-1
For data on s-IGF, see Table 4. To summarize, s-IGF-1 is likely to
be somewhat lower in T1D and not to differ in T2D. Over time,
s-IGF-1 seems to decrease in younger T1D, while it did not differ
in older T1D. This may be caused by a depletion of the insulin
function in the young T1D at follow up. Also, during glycemic
control IGF-1 seems to increase in T2D.
DISCUSSION
In general a major issue is the few histomorphometric studies in
humans (Leite Duarte and da Silva, 1996; Armas et al., 2012), and
the absence of studies on the association between biochemical
markers of bone turnover in blood and actual changes in bone
tissue. Several markers, especially OC, CTX, and P1NP may also
vary with blood glucose or glucose intake, making them perhaps
less markers of bone turnover in diabetics and more markers of
alterations in glucose metabolism. Another issue is kidney func-
tion, which may influence the measurement of several biochemical
markers of bone turnover and also influence histomorphometry
of the bone (Andress et al., 1987).
TYPE 1 DIABETICS VS. NON-DIABETICS
Neither s-calcium nor u-calcium seems to be specific markers
of bone in T1D or differ in comparison to controls (Hamp-
son et al., 1998; Brandao et al., 2007; Abd El Dayem et al.,
2011; Neumann et al., 2011), although young T1D might have
a lower s-calcium (Hamed et al., 2011). Hence may the bone
deficiency, by lower BMD and increased fracture risk (Vester-
gaard, 2007; Vestergaard et al., 2009) in T1D, be formed in child-
hood, leaving the bones fragile in adulthood, while calcium levels
normalize.
Regarding bone turnover markers secreted by bone cells; s-AP,
s-BAP, and s-Scl seem not to differ in T1D compared to con-
trols (Leon et al., 1989; Munoz-Torres et al., 1996; Oz et al.,
2006; Hamed et al., 2011; Gennari et al., 2012), and s-TRAP
seems in normal value range (Munoz-Torres et al., 1996). S-
OC appear to be lower in T1D and may decrease during the
pubertal growth (Brandao et al., 2007; Aboelasrar et al., 2010;
Abd El Dayem et al., 2011); so those diagnosed before adulthood
are bone growth impaired and the bone affection may continue
in adulthood (Danielson et al., 2009; Lappin et al., 2009). The
lack of an association of s-OC with BMD (Munoz-Torres et al.,
1996; Brandao et al., 2007; Danielson et al., 2009) and the posi-
tive relationship to s-CTX (Brandao et al., 2007; Abd El Dayem
et al., 2011) suggest that formation and resorption are coupled
processes in T1D, and may not affect BMD. The negative associa-
tions of s-OC to HbA1c (Danielson et al., 2009; Aboelasrar et al.,
2010; Abd El Dayem et al., 2011) suggest that bone formation is
impaired by high levels of blood glucose; accordingly T1D with
poor glycemic control has more fragile bones than T1D with good
glycemic control.
When looking at bone turnover markers of collagen; s-CTX
and s-CICP are likely to be lower in T1D (Abd El Dayem et al.,
2011; Neumann et al., 2011; Gennari et al., 2012) and u-DPD
may be higher in young T1D (Abd El Dayem et al., 2011), while
u-crosslaps and s-NTX do not differ (Christensen and Svendsen,
1999; Danielson et al., 2009). Seemingly s-CICP is raised, while
bone resorption markers may not differ, be raised or be lowered,
thus making it difficult to conclude definitively. The absence of
a correlation of HbA1c and S-CTX (Lappin et al., 2009), and a
negative correlation to s-NTX (Danielson et al., 2009) suggest that
high HbA1c may affect bone resorption negatively. In young T1D,
s-CTX seems negatively related to pubertal development (Bran-
dao et al., 2007), suggesting that during pubertal development
bone resorption is impaired in T1D. Taken together with the cor-
responding finding regarding s-OC, bone turnover seems to be
reduced during pubertal development in T1D. The RANKL/OPG
system has only been investigated in T1D, where bone resorption
appears to be affected by a reduced OPG. Even so, s-CTX does
not relate to s-OPG, but a positive relationship is apparent with
s-RANKL and the RANKL/OPG ratio (Lappin et al., 2009). Seem-
ingly, s-CTX is a marker of activity in the RANKL system and
might be the end product of the process. Increased blood glucose
seems not to be the mechanism that suppress s-OPG, since s-OPG
is found positively correlated to HbA1c (Galluzzi et al., 2005; Lap-
pin et al., 2009), indicating that increasing levels of blood glucose
inhibit bone resorption.
TYPE 2 DIABETICS VS. NON-DIABETICS
Neither s-calcium nor u-calcium differed between T2D and con-
trols (Gregorio et al., 1994; Hampson et al., 1998; Achemlal et al.,
2005; Oz et al., 2006; Cutrim et al., 2007; Zhou et al., 2010; Garcia-
Martin et al., 2012b; Shu et al., 2012). S-calcium appears not to
correlate to HbA1c or BMD (Levy et al., 1986; Hampson et al.,
1998), thus making it a poor marker of bone- and glycemic-status
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Table 3 | Bone resorption markers.
Marker Study type Reference Diabetes type *
TRAP Glycemic control Campos Pastor et al. (2000) T1D ↓
TRAP-5b Cross-sectional Okuno et al. (2013) Diabetic HD →
Reyes-Garcia et al. (2013) T2D ↓
Garcia-Martin et al. (2012b) T2D ↓
CTX Cross-sectional Rasul et al. (2012b) T2D men PNP ↑
Neumann et al. (2011) T1D women →
Achemlal et al. (2005) T2D men →
Shu et al. (2012) T2D PM →
Rasul et al. (2012a) T2D men vs. women →
Rasul et al. (2012b) T2D women PNP →
Gennari et al. (2012) T1D ↓
Gennari et al. (2012) T2D ↓
Neumann et al. (2011) T1D men ↓
Garcia-Martin et al. (2012b) T2D ↓
Oz et al. (2006) T2D ↓
Dobnig et al. (2006) T2D NH ↓
Reyes-Garcia et al. (2013) T2D ↓
Gerdhem et al. (2005) Diabetic women ↓
Brandao et al. (2007) T1D girls vs. boys ↓
Longitudinal Hamilton et al. (2012) T2D women ↑
T2D men →
T1D men →
T1D women →
s-NTX Cross-sectional Shu et al. (2012) T2D PM →
Danielson et al. (2009) T1D →
u-NTX Cross-sectional Zhou et al. (2010) T2D PM (BMI ≥25) ↑
T2D PM (BMI <25) ↑
Kanazawa et al. (2011b) T2D PM vs. men ↑
Longitudinal Mastrandrea et al. (2008) T1D <20 →
T1D ≥20 →
Glycemic control Kanazawa et al. (2011a) T2D →
Kanazawa et al. (2009b) T2D →
Capoglu et al. (2008) T2D ↓
DPD Cross-sectional Abd El Dayem et al. (2011) T1D ↑
Hampson et al. (1998) T2D PM ↑
Hampson et al. (1998) T1D PM →
Valerio et al. (2002) T1D →
Cutrim et al. (2007) T2D GMC →
T2D PMC →
Oz et al. (2006) T2D →
Gerdhem et al. (2005) Diabetic women ↓
Longitudinal Miazgowski and Czekalski (1998) IDD →
Inaba et al. (1999) T2D →
Miazgowski et al. (2012) T2D PM →
Glycemic control Rosato et al. (1998) NIDD men →
NIDD women →
Capoglu et al. (2008) T2D ↓
(Continued)
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Table 3 | Continued
Marker Study type Reference Diabetes type *
PYR Longitudinal Miazgowski and Czekalski (1998) IDD →
Inaba et al. (1999) T2D →
Rosato et al. (1998) NIDD men ↑
NIDD women ↑
Crosslaps Cross-sectional Christensen and Svendsen (1999) IDD PM vs. PrM ↑
NIDD PM vs. PrM ↑
HP Cross-sectional Gregorio et al. (1994) NIDD PMC ↑
NIDD GMC →
Glycemic control (during the longitudinal study); ∗, statistically significantly different; ↑, significantly higher in diabetics; ↓, significantly lower in diabetics;→, without
significance; GMC, good metabolic control; PMC, poor metabolic control; PM, postmenopausal; NH, nursing home; age ≥70; HD, hemodialysis; PNP, polyneuropathy;
PrM, premenopausal; ≥20, 20 years old or more; <20, younger than 20 years.
Table 4 | Other markers.
Marker Study type Reference Diabetes type *
OPG Cross-sectional Galluzzi et al. (2005) T1D ↑
Lappin et al. (2009) T1D LH ↑
T1D HH ↑
Abd El Dayem et al. (2011) T1D ↓
RANKL Cross-sectional Lappin et al. (2009) T1D LH →
T1D HH →
Scl Cross-sectional Garcia-Martin et al. (2012b) T2D ↑
Gennari et al. (2012) T2D ↑
Adiponectin Cross-sectional Kanazawa et al. (2011b) T2D PM vs. men ↑
Longitudinal Miazgowski et al. (2012) T2D PM ↑
Glycemic control Kanazawa et al. (2009b) T2D →
IGF-1 Cross-sectional Cutrim et al. (2007) T2D GMC →
T2D PMC →
Hamed et al. (2011) T1D ↓
Longitudinal Mastrandrea et al. (2008) T1D <20 ↑
T1D ≥20 →
Glycemic control Rosato et al. (1998) NIDD men ↑
NIDD women ↑
Glycemic control (during the longitudinal study); ∗, statistically significantly different; ↑, significantly higher in diabetics; ↓, significantly lower in diabetics;→, without
significance; GMC, good metabolic control; PMC, poor metabolic control; PM, postmenopausal; LH, low HbA1c <8.5; HH, high HbA1c >8.5.
in T2D. The PTH-vitamin D axis; S-PTH, 1,25OHD, s-25OHD,
and calcitonin are most likely not to be affected in T2D (Pedrazzoni
et al., 1989; Gregorio et al., 1994; Hampson et al., 1998; Achemlal
et al., 2005; Dobnig et al., 2006; Oz et al., 2006; Cutrim et al., 2007;
Zhou et al., 2010; Garcia-Martin et al., 2012b; Gennari et al., 2012;
Shu et al., 2012; Reyes-Garcia et al., 2013). The positive relation-
ship between s-PTH and the resorptive markers s-TRAP-5b and
s-CTX (Reyes-Garcia et al., 2013) suggests that PTH induce bone
resorption in T2D.
Concerning bone turnover markers secreted by bone cells; s-
AP and s-BAP seem not to differ in T2D (Oz et al., 2006; Zhou
et al., 2010; Garcia-Martin et al., 2012b; Shu et al., 2012; Reyes-
Garcia et al., 2013). S-OC and s-TRAP are likely to be decreased
in T2D (Rosato et al., 1998; Achemlal et al., 2005; Dobnig et al.,
2006; Oz et al., 2006; Zhou et al., 2010; Garcia-Martin et al., 2012b;
Shu et al., 2012; Reyes-Garcia et al., 2013) and s-Scl, which impair
bone formation (Manolagas and Almeida, 2007; Gennari et al.,
2012), seems increased, suggesting that T2D is in a state of low
bone turnover. S-OC seems and s-Scl tends to correlate nega-
tively to HbA1c in T2D (Dobnig et al., 2006; Kanazawa et al.,
2009a; Garcia-Martin et al., 2012b; Gennari et al., 2012), thus
suggesting that the low bone turnover and bone deficiency in
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FIGURE 2 | Overview of bone markers that are likely to differ in
diabetics compared to controls. Both T1D and T2D appear to have altered
bone resorption markers and bone formation markers, where bone
formation markers (OC, P1NP, CICP) are lowered, while bone resorption
markers (DPD, u-NTX, CTX, TRAP) are either lowered or raised. This reveals
a dissociation in the bone markers among diabetics, as bone markers that
do not differ are left out of the figure. ↑ Indicates raised marker, ↓ indicates
lowered marker, blue circle surrounds markers that appear to be lowered,
green circle surrounds markers that seem to be raised, red circle surrounds
diabetics.
T2D may be caused by elevated glycemic levels. S-BAP have a
negative relationship with IGF-1 (Kanazawa et al., 2009a, 2011b),
while s-OC is in positive relationship with IGF-1 (Kanazawa et al.,
2009a), proposing that IGF-1 is a marker of bone formation in
T2D specific to OC. S-BAP, s-TRAP-5b, and s-CTX correlated neg-
atively to s-Scl (Garcia-Martin et al., 2012b; Gennari et al., 2012),
thus Scl correlates to decreased bone turnover, while it in contrast
correlated to increased BMD (Garcia-Martin et al., 2012b). The
increase in BMD is inconsistent with the antagonizing effect on
the Wnt-pathway (Manolagas and Almeida, 2007). When look-
ing at bone turnover markers of collagen; u-NTX is higher (Zhou
et al., 2010) and s-NTX, s-PICP, s-CICP, and u-DPD seem not to
differ (Hampson et al., 1998; Oz et al., 2006; Cutrim et al., 2007;
Shu et al., 2012), while u-crosslaps, s-CTX, and s-P1NP are lower
(Christensen and Svendsen, 1999; Dobnig et al., 2006; Oz et al.,
2006; Garcia-Martin et al., 2012b; Gennari et al., 2012; Shu et al.,
2012; Reyes-Garcia et al., 2013), suggesting that bone turnover
is changed in T2D. The differences in bone resorption markers
may reflect different points of progress in T2D bone affection or
the fact that markers may be sensitive or insensitive in T2D. The
markers may also be affected by the heterogeneity of the T2D state.
Also, S-CTX is negatively related to and P1NP tends to negatively
relate to HbA1c (Achemlal et al., 2005; Dobnig et al., 2006; Shu
et al., 2012), while u-HP is positively related to HbA1c (Gregorio
et al., 1994) and u-NTX does not relate to HbA1c (Kanazawa et al.,
2009a). Apparently elevated levels of blood glucose suppress bone
formation, and decrease or increase markers of bone resorption
in T2D, which is consistent with the findings concerning s-OC
and s-Scl. Therefore blood glucose may have taken part in the
previous mentioned fluctuating pattern of the resorption mark-
ers. The negative relationship between S-CTX, u-NTX, and BMD
(Reyes-Garcia et al., 2013), suggest these markers as informants on
BMD and that extensive bone resorption cause low BMD.
Concerning fat tissue hormones; adiponectin and leptin may
have a positive effect on bone status by suppressing resorptive
markers, increasing bone formation markers and BMD (Tamura
et al., 2007; Kanazawa et al., 2011b). However, this is uncertain and
further studies are needed.
TYPE 1 VS. TYPE 2 DIABETICS
The lack of a difference in bone turnover markers indicate that
T1D and T2D (Hampson et al., 1998; Gennari et al., 2012) are not
different regarding the effect on bone markers, although Scl levels
are higher in T2D (Gennari et al., 2012), proposing that bones are
affected through an antagonizing effect on the WNT-pathway in
T2D, but not in T1D. However the full selection of bone markers
is not represented.
HOW SEVERITY OF DISEASE AFFECTS MARKERS
Severity of disease is characterized by diabetics with polyneuropa-
thy or diabetics in hemodialysis. S-P1NP is reported higher in
T2D with polyneuropathy than regular T2D otherwise no mark-
ers differ (OC and s-BAP) (Rasul et al., 2012b). In diabetics in
hemodialysis s-ucOC and s-PTH are lower, while s-TRAP-5b and
s-BAP do not differ in comparison to equally ill controls (Okuno
et al., 2013). More severe diabetes is likely to affect bone markers
by raising P1NP and lowering s-ucOC, this may be caused by the
severe disease itself.
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DURATION OF DIABETES AND THE EFFECT ON BONE
S-OC in T1D (Abd El Dayem et al., 2011) and S-TRAP-5b in
T2D (Reyes-Garcia et al., 2013), are negatively correlated to the
duration of diabetes. This suggests that long term diabetes lead to
suppressed bone turnover and thus potentially fragile bones.
THE EFFECT OF TIME ON MARKERS IN TYPE 1 DIABETICS
The markers s-OC, s-CTX, u-PYR, u-DPD are likely not to differ
over time (Miazgowski and Czekalski, 1998; Mastrandrea et al.,
2008; Hamilton et al., 2012), suggesting that bone turnover does
not change over time in T1D and support the hypothesis that bone
turnover is lowered during puberty, since none of the available
longitudinal studies have investigated a young T1D population.
THE EFFECT OF TIME ON MARKERS IN TYPE 2 DIABETICS
The resorption marker s-CTX increase over 5 years, while no
other bone turnover marker seems to change (Miazgowski and
Czekalski, 1998; Hamilton et al., 2012), suggesting either no change
in bone turnover over time, thus the s-CTX increase may be seen by
chance, or that s-CTX is a specific marker in T2D, where others are
not. An increase in s-25OHD may affect this; even so PTH did not
change (Miazgowski and Czekalski, 1998; Hamilton et al., 2012).
The s-adiponectin increase before it normalized back to baseline
level in newly diagnosed in the study by Miazgowski et al. (2012)
suggest, together with a negative relationship to BMD, that a quick
rise and following normalization in s-adiponectin may lower BMD
in T2D. On the other hand, changes in femoral neck BMD seems
to relate positively to baseline log [adiponectin] (Kanazawa et al.,
2010), which does not accord to the above. Over time HbA1c does
not seem to be related to u-DPD, s-BAP (Kanazawa et al., 2010;
Miazgowski et al., 2012), suggesting that HbA1c does not affect
bone turnover markers.
THE CHANGES BY GLYCEMIC CONTROL
Seven years of intensive insulin therapy decrease s-TRAP, while
bone formation markers did not change in T1D (Campos Pas-
tor et al., 2000), indicating that glycemic control alters bone
resorption, while it has no effect on bone formation.
The intervention of glycemic control is, in T2D, executed
by regular diabetes control, diet, exercise, or medical treatment.
The glycemic control seems not to change s-BAP, ucOC, s-PTH,
s-25OHD, and s-adiponectin, while u-PYR and s-IGF-1 seem
to increase, and u-DPD, u-HP, u-calcium, and u-NTX seem to
decrease (Gregorio et al., 1994; Rosato et al., 1998; Capoglu et al.,
2008; Kanazawa et al., 2009b). S-OC may not change, increase, or
decrease during glycemic control (Gregorio et al., 1994; Capoglu
et al., 2008; Kanazawa et al., 2009b, 2011a), where a short period of
glycemic control increase s-OC, intermediate periods decrease s-
OC, and the longest available period of glycemic control (2 years)
increase s-OC (Rosato et al., 1998). The previously proposed pos-
itive effect of glycemic control on OC may be present, however
the link between OC and glycemic control seems ambiguous due
to the different reports. In general; bone resorption may decrease
during glycemic control, although u-PYR increase, and bone for-
mation may not change. PYR is not as good a bone marker as DPD,
since it is not specific for bone tissue, so to say it is most likely that
bone resorption is lowered in T2D, and the PYR increase could be
due to collagen breakdown at non-bone sites, suggesting glycemic
control to decrease bone resorption.
COHORTS
The data on biochemical markers was collected from several
records as mentioned in the Section “Methods.” In general the
studies used small cohorts consisting of around 50 diabetics and
a similar control group. The studies on T2D have larger cohorts
than studies on T1D, whereas the largest T1D cohort is of 128 par-
ticipants (Neumann et al., 2011), while the largest diabetic cohort
by far is found in Zhou et al. (2010) where 890 postmenopausal
T2D were examined. Another aspect is that the cohorts were very
heterogeneous in age and postmenopausal status among women.
Most studies on T2D included have a mean age around 60 and
if they included women, they were postmenopausal, although
other studies have older or younger populations. In opposition
the studies examining T1D primarily looked at younger popu-
lations and a larger fraction of the studies assessed bone status
in children and/or adolescents. The studies have different means
by assessing diabetes in their participant; some use criteria by
WHO or American Diabetes Association, while others retrieve
the patients from hospitals and outpatient clinics and a study
does not mention how they got their diabetic participants (Okuno
et al., 2013). However all these methods, except the last mentioned,
seem reliable and therefore the results seem to consider diabetics.
Another problem in comparing the results of the studies is the
difference in diabetes duration. T1D cohorts have been reported
with mean diabetes duration varying from 2.67 (Hamed et al.,
2011) to 18.5 years (Gennari et al., 2012). For T2D the variation
in time since diagnosis spans from a diagnosis made within the
last year (Miazgowski et al., 2012) to 14.3 years (Tamura et al.,
2007). This is an issue, since diabetes duration seems to affect
bone turnover markers negatively and therefore makes it hard to
compare the studies with different disease durations. Regarding
the longitudinal studies; their period of follow up differs from
1 month (Kanazawa et al., 2009b) to 7 years (Campos Pastor et al.,
2000), which may question the comparability of the results. Many
confounders are also likely to influence the results including co
morbidities, diabetes medication, other medications, and base-
line characteristics as BMI, smoking, and alcohol. Even though
most studies exclude participants with bone metabolism related
diseases and bone metabolism affecting treatment their exclusion
criteria are not unanimous. Also T2D is in the available records
medically treated very differently. Some receive only diet changes,
while others receive oral anti diabetics and others again insulin or
a mix of different treatment modalities. This is a subject of con-
cern regarding the reliability of the comparability of the different
results.
The small cohorts, the heterogeneity among the studies regard-
ing age, menopausal state, diabetes duration, exclusion criteria,
and diabetes treatment may affect the results on the bone turnover,
whereas truly hidden bone affection may be hidden in the large
number of confounders.
CLOSING REMARKS
The paradox of increased Scl and yet increased BMD in T2D, may
be partly explained by inflammation. Inflammation is a part of
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both the T1D and the T2D disease (Bending et al., 2012; Calle
and Fernandez, 2012). This may affect the bone markers and Scl
as in inflammatory diseases, which is linked to bone resorption
and osteoporotic fractures (Lacativa and Farias, 2010). Hence the
effect on certain bone markers, as concluded in this review, may
be due to inflammation.
The differences in bone turnover markers may also relate to
the fact, that some markers are specific in diabetics, while oth-
ers are not. The specificity of markers could be due to diabetes
per se or the results of diabetes by blood glucose alterations,
insulin deficiency, and AGE. Elevated blood glucose may result in
measurement errors regarding bone markers, which could explain
these differences. In addition cohort differences may influence the
findings and hide the true effect of diabetes on bone markers by
confounders. In experimental rat models, where the human con-
founders are not present, bone markers as OC, PYR, and TRAP-5b
are reported decreased in diabetic rats in comparison to controls
(Herrero et al., 1998; Suzuki et al., 1998). Therefore supporting
that bone markers and bone turnover are lowered in the diabetic
state and the fluctuating pattern in humans may be due to other
effects than diabetes per se. However the findings regarding rats
may not be transferable to humans. In conclusion the alteration of
bone turnover in T1D and T2D may be mediated through elevated
blood glucose levels and long duration of diabetes.
PERSPECTIVES
In general bone formation and resorption are tightly coupled, and
formation markers and resorptive markers tend to change in a
coordinated way. The dissociation seen in diabetes, where some
markers decrease (both formation markers, such as OC in both
T1D and T2D, and resorption markers such as CTX and TRAP in
T2D), whereas the remainder do not (e.g., AP) could point to a
very specific uncoupling effect on these of factors associated with
the disruption in glucose metabolism in diabetes. Perhaps glucose
alters the circulating levels without affecting bone turnover per se.
This may be supported by the only histomorphometric study in
humans with T1D, which showed no alteration in bone turnover
(Armas et al., 2012). However, more research is needed, per-
haps including modern PET scanning techniques using fluoride
to elucidate bone turnover (Puri et al., 2012).
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